Compare Oracle Corporation (ORCL) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oracle Corporation vs Zoetis Inc — how do they compare? Oracle Corporation trades at $162.65 (market cap $468.13B), while Zoetis Inc trades at $73.51 (market cap $30.40B). The key difference: Oracle Corporation is far larger — about 15.4× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.88%). Which is the better fit depends on your goals.
| ORCL | ZTS | |
|---|---|---|
Market Cap | $468.13B | $30.40B |
Sector | Technology | Health |
52-Week High | $328.33 | $150.61 |
52-Week Low | $114.99 | $71.91 |
Enterprise Value | $597.38B | $37.96B |
Dividend Yield | 1.23% | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Oracle (ORCL) trades at $161.70, up 1.81% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $57.40B in 2025, with net income margin expanding to 25.37%. The stock is supported by positive AI infrastructure developments and a consensus analyst price target of $243.38, indicating significant upside potential from current levels.
The outlook remains positive driven by AI partnerships and cloud growth, but risks include high valuation multiples and rising capital expenditures. Institutional sentiment is bullish with 65% buy ratings, though legal scrutiny and competitive pressures warrant monitoring for sustained momentum.
Zoetis (ZTS) trades at $73.60, down 2.92% amid bearish technical signals and mixed earnings. The stock faces pressure from weakening U.S. companion animal sales and competitive headwinds, though profitability remains strong with 71.67% gross margins and 27.69% net income margin. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a guidance cut. Analyst consensus is divided with 45% Buy ratings and a $93.40 price target, suggesting 27% upside from current levels.
The outlook balances valuation appeal (P/E of 12) against near-term operational challenges. Investment opportunity lies in market dominance and robust cash flow generation, while risks include sustained pet health demand softness and competitive pricing pressure. The stock trades near support at $73, with institutional sentiment mixed amid recent portfolio adjustments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oracle Corporation
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
